small medium large |  
print   |   Bookmark & Share share
Profile Image

Senior Investigator

David R. Sibley, Ph.D.

Molecular Neuropharmacology Section

Building 35 Room 3A201
35 Convent Drive MSC3723
Bethesda MD 20892-3723
Office: (301) 496-9316
Lab: (301) 496-6329
Fax: (301) 480-3726

Dr. Sibley received his B.S. degree in Biology from San Diego State University and his Ph.D. in Physiology/Pharmacology from the University of California, San Diego where he worked with Ian Creese studying the ligand binding properties of dopamine receptors. He subsequently carried out postdoctoral work with Robert Lefkowitz at Duke University where he characterized adrenergic receptor regulatory mechanisms. Dr. Sibley moved to the NINDS in 1987 and was appointed Chief of the Molecular Neuropharmacology Section in 1992. His laboratory is currently investigating the molecular, cellular and biochemical properties of dopamine receptors and their role in neuronal signaling.

The long-term goal of the Molecular Neuropharmacology Section is the characterization of neurotransmitter receptor-mediated information transduction, and its regulation, across neuronal membranes. The primary model systems under investigation are those neurotransmitter receptors that are linked to their signal transduction pathways via guanine nucleotide binding regulatory (G) proteins with specific emphasis on dopamine receptor subtypes. Specific G proteins have been shown to link these receptors to the activation and inhibition of various nucleotide cyclases, phospholipases, and several ion channels. In order to characterize these receptors at the biochemical and molecular levels and study their regulation, there are several ongoing interrelated lines of research. Such projects include investigating receptor structure/function/pharmacology relationships, receptor-effector coupling mechanisms, G protein interactions, and molecular mechanisms of receptor desensitization and intracellular trafficking. We are also interested in using high throughput screening approaches to develop novel ligands for modulating dopamine receptor expression and signaling. These ligands may prove useful in the development of novel pharmacological therapies for treating numerous neurological and psychiatric disorders associated with aberrant dopaminergic signaling.

Staff Image
  • Emmanuel Akano, M.D.
    Clinical Fellow

  • Caroline Cuoco, B.S.
    Post baccalaureate IRTA Fellow

  • Marilyn Day, B.S.
    Post baccalaureate IRTA Fellow

  • Megan Donegan, M.S.
    Biologist and Lab Manager

  • Chelesa Fearce, B.S.
    Post baccalaureate IRTA Fellow

  • R. Benjamin Free, Ph.D.
    Staff Scientist
    (301) 443-4785

  • Kathryn D. Luderman, Ph.D.
    Postdoctoral Fellow
    (301) 402-0880

  • Amy Moritz, Ph.D.
    Postdoctoral Fellow
    (301) 443-4790

  • Marta Sanchez Soto, Ph.D.
    Postdoctoral Fellow

  • Blair Willette, B.S.
    Post baccalaureate IRTA Fellow

  • 1) Kumar, V., Moritz, A.E., Keck, T.M., Bonifazi, A., Ellenberger, M., Sibley, C.D., Free, B.F., Shi, L., Lane, J.R., Sibley, D.R.*, and Newman, A.H.* (*corresponding authors) (2017)
  • Synthesis and pharmacological characterization of a novel series of trans-cyclopropylmethyl-linked 4-phenylpiperazine analogues that exhibit selectivity and allosteric pharmacology at the dopamine D3 receptor (D3R)
  • Journal of Medicinal Chemistry, 60, 1478–1494
  • 2) Zou, M.-F., Keck, T.M., Kumar, V., Donthamsetti, P., Michino, M., Burzynski, C., Schweppe, Bonfazi, A., Free, R.B., Sibley, D.R., Janowsky, A., Shi, L., Javitch, J.A., Newman, A.H. (2016)
  • Novel analogs of (R)-5-(methylamino)-5,6,-dhydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (sumanirole) provide clues to dopamine D2/D3 receptor agonist selectivity
  • Journal of Medicinal Chemistry, 59, 2973–2988
  • 3) Dix, A.V., Conroy, J.L., Rosenker, K.M., Sibley, D.R., Appella, D.H. (2015)
  • PNA-Based Multivalent Nanoscaffolds Activate the Dopamine D2 Receptor
  • Medicinal Chemistry Letters, 13, 425-429
  • 4) Michino, M., Free, R.B., Sibley, D.R., and Shi, L. (2015)
  • Structural basis for Na+ sensitivity in dopamine D3 and D3 receptors
  • Chemical Communications, 51, 8618-8621
  • 5) Furman, C.A., Roof, R.A., Moritz, A., Miller, B.N., Doyle, T.B., Free, R.B., Banala, A.K., Paul, N.M., Kumar, V., Sibley, C.D., Newman, A.H., Sibley, D.R. (2015)
  • Investigation of the binding and functional properties of extended-length D3 dopamine receptor-selective antagonists
  • European Neuropsychopharmacology, 25, 1448-1461
  • 6) Meade, J.A., Free, R.B., Miller, N.R., Doyle, T.B., Moritz, A.E., Conroy, J.L., Chun, L.S., Watts, V.J., and Sibley, D.R. (2015)
  • (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and ß-arrestin-mediated signaling
  • Psychopharmacology, 232, 917-930
  • 7) Conroy, J.L., Free, R.B., and Sibley, D.R. (2015)
  • Identification of G protein-biased agonists that fail to recruit ß-arrestin or promote internalization of the D1 dopamine receptor
  • ACS Chemical Neuroscience, 6: 681-692
  • 8) Xiao, J., Free, R.B., Barnaeva, E., Conroy, J.L., Doyle, T.B., Miller, B., Bryant-Genevier, M., Taylor, M.K., Hu. X., Dulcey, A. E., Southall, N., Ferrer, M., Titus, S., Zheng, Z., Sibley, D.R., and Marugan, J.J. (2014)
  • Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists
  • Journal of Medicinal Chemistry, 57, 3450-3463
  • 9) Free, R.B., Chun, L.S., Moritz, A.E., Miller, B., Doyle, T.B., Conroy, J.L., Padron, Meade, J.A., Xiao, J., Hu, X., Dulcey, A.E., Han, Y., Duan, L., Titus, Bryant-Genevier, M., Barnaeva, E., Ferrer, M., Javitch, J.J., Beuming, T., Shi, L., Southall, N., Marugan, J.J., and Sibley, D.R. (2014)
  • Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor
  • Molecular Pharmacology, 86:96-105
  • 10) Chun, L.S., Free, R.B., Doyle, T.B., Huang, X.-P., Rankin, M.L., and Sibley, D.R. (2013)
  • D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms
  • Molecular Pharmacology, 84, 190-200
  • 11) Frederick, A.L., Yano, H., Trifilieff, P., Vishwasrao, H.D., Biezonski, D., Meszaros, J., Sibley, D.R., Kellendonk, C., Sonntag, K.C., Graham, D.L., Colbran, R.J., Stanwood, G.D., and Javitch, J.A. (2015)
  • Evidence against dopamine D1/D2 receptor heteromers
  • Molecular Psychiatry, 20, 1373-1385
  • 12) Yang, S., Yang, Y., Yu, P., Yang, J., Villar, V.A.M., Sibley, D.R., Jose, P.A., Chunyu, Z. (2015)
  • Dopamine D1 and D5 Receptors Differentially Regulate Oxidative Stress through Paraoxonase 2 in Kidney Cells
  • Free Radical Research, 49, 397-410
  • 13) Ennis, R.C., Asico, L.D., Armanso, I., Yang, J., Feranil, J.B., Jurgens, J.A., Escano, C.S., Yu, P., Wang, X., Sibley, D.R., Jose, P.A., Villar, V.A.M. (2014)
  • The D1-like receptors regulate the α1A adrenergic receptor in human renal proximal tubule cells and D1-like receptor knockout mice
  • American Journal of Physiology, 307(11): F1238-1248
  • 14) Bergman, J., Roof, R.A., Furman, C.A., Conroy, J.L., Mello, N.K., Sibley, D.R., and Skolnick, P., (2013)
  • Modification cocaine self-administration by buspirone (Buspar®): potential involvment of D3 and D4 dopamine receptors
  • International Journal of Neuropsychopharmacology, 16, 445-458
  • 15) Maison, S.F., Liu, X.-P., Eatock, R.A., Sibley, D.R., Grandy, D.K., and Liberman, M.C. (2012)
  • Dopaminergic signaling in the cochlea: receptor expression patterns and deletion phenotypes
  • Journal of Neuroscience, 32, 344-355
  • 16) Newman, A.H., Blaylock, B.L., Nader, M.A., Bergman, J., Sibley, D.R., Skolnick, P. (2012)
  • Medication Discovery for Addiction: Translating the Dopamine D3 Receptor Hypothesis
  • Biochemical Pharmacology, 84, 882-890
  • 17) P.F. Kramer, C.H. Christensen, L.A. Hazelwood, A. Dobi, R. Bock, D.R. Sibley, Y. Mateo and V.A. Alvarez (2011)
  • Dopamine D2 receptor overexpression alters behavior and physiology in Drd2-EGFP mice
  • J Neuroscience, 31, 126-32
  • 18) Skinberb, M., Sibley, D.R., Javitch, J.A., and Abi-Dargham, A. (2011)
  • Imaging the High Affinity State of the Dopamine D2 Receptor: fact or fiction
  • Biochemical Pharmacology, 83, 193-198
  • 19) Reichart, D.L., Hinkle, R.T., Lefever, F.R., Dolan, E.T., Dietrich, J.A., Sibley, D.R., and Isfort, R.J. (2011)
  • Activation of the dopamine D1 receptor increases skeletal muscle mass and force production
  • BMC Musculoskeletal Disorders, 12, 27-35
  • 20) Banala, A.K., Levy, B.A., Khatri, S.S., Furman, C.A., Roof, R.A., Mishra, Y., Griffin, S.A., Sibley, D.R., Luedtke, R.R., Hauk-Newman, A. (2011)
  • N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl) piperazine-1-yl)-butyl)-aryl carboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity
  • Journal of Medicinal Chemistry, 54, 3581-3594
  • 21) Asico, L., Zhang, X. Jiang, J. Cabrera, D. Escano, C. Sibley, D.R. Wang, X. Yang, Y., Mannon, R. Jones, J. Armando, I. Jose, P.A. (2011)
  • Lack of renal dopamine D5 receptors promotes hypertension,
  • Journal of the American Society of Nephrology, 22, 82-89
  • 22) Rankin, M.L., and Sibley, D.R. (2010)
  • Consitutive phosphorylation by protein kinase C regulates D1 dopamine receptor signaling
  • Journal of Neurochemistry, 115, 1655-1667
  • 23) Skinbjerb, M., Seneca, N., Liow, J.-S., Hong, J., Weinschenker, D., Pike, V.W., Halldin, C., Sibley, D.R., and Innis, R.B. (2010)
  • Dopamine-β-hydroxylase deficient mice have normal densities of D2 dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding data
  • Synapse, 64, 699-703
  • 24) Skinberg, M., Liow, J.-S., Seneca, N., Hong, J., Lu, S., Thorsell, A., Heilig, M., Pike, V.W., Halldin, V., Sibley, D.R., and Innis, R.B. (2010)
  • Dopamine D2 receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-defective mouse model
  • Neuroimage, 50, 1402-1407
  • 25) Wang, X., Luo, Y., Escano, C.S., Yang, Z., Asico, L., Li, H., Jones, J.E., Armando, I., Lu, Q., Sibley, D.R., Eisner, G.M., Jose, P.A. (2010)
  • Upregulation of renal sodium transporters in D5 dopamine receptor deficient mice
  • Hypertension, 55, 1431-1437
  • 26) Rex, E., Rankin, M.L., Yang, Y., Lu, Q., Gerfen, C.R., and Sibley, D.R. (2010)
  • Identification of RanBP9/10 as interacting partners for protein kinase Cs γ/δ and the D1 dopamine receptor: regulation of PKC-mediated receptor phosphorylation
  • Molecular Pharmacology, 78, 69-80
  • 27) Skinbjerb, M., Namkung, Y., Halldin, C., Innis, R.B., and Sibley, D.R. (2009)
  • Pharmacological characterization of 2-methoxy-N-propylnorapomorphine’s (MNPA) interactions with D2 and D3 dopamine receptors
  • Synapse, 63, 462-475
  • 28) Skinbjerb, M., Ariano, M.A., Thorsell, A., Heilig, M., Halldin, C., Innis, R.B., and Sibley, D.R. (2009)
  • Arrestin3 mediates D2 Dopamine receptor internalization
  • Synapse, 63, 621-624
  • 29) Sahu, A., Tyeryar, K.R., Vongtau, H.O., Sibley, D.R., and Undie, A.S. (2009)
  • D5 dopamine receptors are required for dopaminergic activation of phospholipase C
  • Molecular Pharmacology, 75, 447-453
  • 30) Free RB, Hazelwood LA, Sibley DR. (2009)
  • Identifying novel protein-protein interactions using co-immunoprecipitation and mass spectroscopy.
  • Curr Protoc Neurosci., Chapter 5, Unit 5.28
  • 31) Namkung, Y., Dipace, C., Urizar, U., Javitch, J.A., and Sibley, D.R. (2009)
  • G protein-coupled receptor kinase-2 constitutively regulates D2 receptor expression and signaling independent of receptor phosphorylation
  • Journal of Biological Chemistry, 284, 34103-34115
  • 32) Namkung, Y., Dipace, C., Javitch, J.A., and Sibley, D.R. (2009)
  • G protein-coupled receptor kinase-mediated phosphorylation mediates post-endocytic trafficking of the D2 dopamine receptor
  • Journal of Biological Chemistry, 284, 15038-15051
  • 33) Kim, O.J., Ariano, M.A., Namkung, Y., Marinec, P., Kim, E., Han, J., and David R. Sibley (2008)
  • D2 dopamine receptor expression and trafficking is regulated through direct interactions with ZIP
  • Journal of Neurochemistry, 106, 83-95
  • 34) Rex, E.B., Rankin, M.L., Ariano, M.A., and Sibley, D.R. (2008)
  • Ethanol Regulation of D1 Dopamine Receptor Signaling is Mediated by Protein Kinase C in an Isozyme-Specific Fashion
  • Neuropsychopharmacology, 32, 2900-2911
  • 35) Hazelwood, L.A., Free, B.F., Cabrera, D.M., Skinbjerb, M., and Sibley, D.R. (2008)
  • Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+, K+-ATPase
  • Journal of Biological Chemistry, 283, 36441-36453
  • 36) Argilli, E., Sibley, D.R., Malenka, R.C., England, R.C., England, P.M., and Bonci, A. (2008)
  • Mechanism and time course of cocaine-induced LTP in the VTA
  • Journal of Neuroscience, 28, 9092-9100
  • 37) O�Sullivan, G., Dunleavy, M., Hakansson, K., Kinsella, A., Croke, D.T., Fienberg, A.A., Greengard, P., Sibley, D.R., Fisone, G., Henshall, D.C., and Waddington, J.L. (2008)
  • Dopamine D1 vs D5 Receptor-Dependent Induction of Seizures Involves DARPP-32 and ERK1/2 Signalling
  • Neuropharmacology, 54, 1051-1061
  • 38) Karlsson, R.M., Hefner, K.R., Sibley, D.R., and Holmes, A. (2008)
  • Comparison of dopamine D1 and D5 receptor knockout mice for cocaine locomotor sensitization
  • Psychopharmacology, 100, 117-127
  • 39) Seneca, N., Zoghbi, S.S., Skinbjerb, M., Liow, J.-S., Hong, J., Sibley, D.R., Pike, V.W., Haldin, C., Innis, R.B. (2008)
  • Occupancy of Brain D2/3 Receptors in Rat Brain by Endogenous Dopamine Measured with the Agonist Positron Emission Tomography Radioligand [11
  • Synapse, 65, 756-763
  • 40) Seneca, N., Skinbjerb, M., Zoghbi, S.S., Liow, J.-S., Hong, J., Gladding, R.L., Hong, J., Kannan, P., Tuan, E., Sibley, D.R., Haldin, C., Pike, V.W., Innis, R.B (2008)
  • Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA, a dopamine agonist radioligand
  • Synapse, 62, 700-709
  • 41) Li, H. Armando, I., Yu, P., Escano, C., Mueller, S., Asico, L., Pascua, A., Lu, Q., Villar, V., Jones, J., Periasamy, A., Creswell, K., Guillemette, G., Sibley, D.R., Felder, R., Jose, P.A. (2008)
  • Dopamine D5 receptors mediate AT1 angiotensin receptor degradation via ubiquitin-proteosome pathway
  • Journal of Clinical Investigation, 118, 2180-2189
  • 42) Wang, Z., Armando, I., Asico, L.D., Escano, C., Wang, X., Felder, R.A., Schnackenberg, C.G., Sibley, D.R., Robillard, J.E., Eisner, G.M., and Jose, P.A. (2007)
  • The Elevated Blood Pressure of Human GRK4γ A142V Transgenic Mice is not Associated with Increased ROS Production
  • American Journal of Physiology, 292(5), H2083-2092
  • 43) Hernandez-Echeagaray, E., Cepeda, C., Ariano, M.A., Lobo, M.K., Sibley, D.R., and Levine, M.S. (2007)
  • Dopamine Reduction of GABA Currents in Medium-sized Spiny Neurons is Principally Mediated by the D1 Receptor Subtype
  • Neurochemical Research, 32, 229-240
  • 44) Free, R.B., Hazelwood, L.A., Namkung, Y., Cabrera, D.M., Spalding, H.N., Rankin, M.L., and Sibley, D.R., (2007)
  • D1 and D2 Dopamine Receptor Expression is Regulated by Direct Interaction with the Chaperone Protein Calnexin
  • Journal of Biological Chemistry, 282, 2185-21300
  • 45) Yang, Z., Asico, L.D., Yu, P., Wang, Z., Jones, J.E., Escano, C.S., Quinn, M.T., Sibley, D.R., Romero, G.G., Felder, R.A., and Jose, P.A. (2006)
  • D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure in mice
  • American Journal of Physiology, 290(1), R96-R104
  • 46) Tomiyama, K., Makihara, Y., Yamamoto, H., O’Sullivan, G., Nally, R.E., Tighe, O., Kinsella, A., Fienberg, A.A., Grandy, D.K., Greengard, P., Low, M.J., Rubinstein, M., Sibley, D.R., Croke, D.T., Koshikawa, N., and Waddington, J.L. (2006)
  • Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 or DARPP-32 �knockout�
  • European Neuropsychopharmacology, 16, 437-445
  • 47) Rankin, M.L., Marinec, P.S., Cabrera, D.M., and Sibley, D.R. (2006)
  • The D1 Dopamine Receptor is Constitutively Phosphorylated by G Protein Coupled Receptor Kinase 4: evidence for a novel mechanism of regulation
  • Molecular Pharmacology, 69, 759-769 (see "Perspectives" article in same issue)
  • 48) Yang, Z., Asico, L.D., Yu, P., Wang, Z., Jones, J.E., Bai, R., Sibley, D.R., Felder, R.A., and Jose, P.A. (2005)
  • D5 Dopamine Receptor Regulation of Phospholipase D
  • American Journal of Physiology, 288(1), H55-61
  • 49) Sullivan, G.J., Kinsella, A., Sibley, D.R., Tighe, O., Croke, D.T., and Waddington, J.L. (2005)
  • Ethological Rsolution of Behavioral Topography and D1-like vs D2-like Agonist Responses in Congenic Dopamine D5 Receptor Mutants: Identification of D5:D2-like Interactions
  • Synapse, 55, 201-211
  • 50) Kudwa, A.E., Dominguez-Salazar, E., Cabrera, D.M., Sibley, D.R. and Rissman, E.F. (2005)
  • Dopamine D5 Receptor Modulates Male and Female Sexual Behavior in Mice
  • Psychopharmacology, 180, 206-214
  • 51) Zeng, C., Yang, Z., Jones, J. Wang, X., Altea, J., Mangrum, A.J., Hopfer, U., Sibley, D.R., Eisner, G.M., Felder, R.A., and Jose, P.A. (2005)
  • Interaction of AT1 and D5 dopamine receptors in renal proximal tubule cells
  • Hypertension, 45, 804-810
  • 52) Kim, O.-J., Gardner, B.R., Williams, D.B., Marinec, P.S., Cabrera, D.M., Peters, J.D., Mak, C.C., Kim, K.-M. and Sibley, D.R. (2004)
  • The Role of Phosphorylation in D1 Dopamine Receptor Desensitization: Evidence for a Novel Mechanism of Arrestin Association
  • Journal of Biological Chemistry, 279, 7999-8010
  • 53) Laplante, F., Sibley, D.R. and Quirion, R. (2004)
  • Reduction in Acetylcholine Release in the Hippocampus of Dopamine D5 Receptor Deficient Mice
  • Neuropsychopharmacology, 29, 1620-1629
  • 54) Homes, A., Lachowicz, J.E. and Sibley, D.R. (2004)
  • Dopamine Receptor Knockout Mice Reveal New Insights into Receptor Function and Pharmacology
  • Neuropharmacology, 47/8, 1117-1134
  • 55) O'Sullivan, G.J., Clifford, J.J., Tomiyama, K., Koshikawa, N., Drago, J., Sibley, D.R., Croke, D.T., an Waddington, J.L. (2004)
  • D1-like Dopamine Receptor-Mediated Function in Congenic Mouse Mutants with D1 versus D5 Receptor Knockout
  • Journal of Receptors and Signal Transduction, 24, 107-116
  • 57) Namkung, Y. and Sibley, D.R. (2004)
  • Protein Kinase C Mediates Phosphorylation, Desensitization and Trafficking of the D2 Dopamine Receptor
  • Journal of Biological Chemistry, 279, 49533-49541
  • 58) Elliot, E.E., Sibley, D.R., and Katz, J.L. (2003)
  • Behavioral Effects of Cocaine in Dopamine D5 Receptor Knockout Mice
  • Psychopharmacology, 169, 161-168
  • 59) Lachowicz, J.E. and Sibley, D.R. (2003)
  • Dopaminergic Receptor Function Defined by Studying Genetically Alterered Mice
  • In Dopamine Receptors and Transporters, pp 295-320
  • 60) Schetz, J.A., Kim, O.J., Sibley, D.R. (2003)
  • Pharmacological Characterization of Mammalian D1 and D2 Dopamine Receptors Expressed in Drosophila Schneider-2 Cells
  • Journal of Receptors and Signal Transduction, 23, 99-109
  • 61) Shapiro, D.A., Renock, S., Arington, E., Chiodo, L.A., Sibley, D.R., Roth, B.L., and Mailman, R., (2003)
  • Aripiprazole, a Novel Atypical Antipsychotic with a Unique and Robust Pharmacology
  • Neuropsychopharmacology, 28, 1400-1411
  • 62) Sibley, D.R., Gardner, B, Peters, J.D., and Kim, O.-J. (2002)
  • Structural Insights into D1 Dopamine Receptor Phosphorylation and Desensitization
  • In Catecholamine Research: From Molecular Insights to Clinical Medicine, pp 159-162
  • 63) Ariano, M.A., Aronin, N., DiFiglia, M., Tagle, D.A., Sibley, D.R., Leavitt, B.R., Hayden, M.R. and Levine, M.S. (2002)
  • Striatal Neurochemical Changes in Transgenic Models of Huntington's Disease
  • Journal of Neuroscience Research, 68, 716-729
  • 64) Hollon, T.R., Bek, M.J., Lachowicz, J.E., Ariano, M.A., Mezey, E., Ramachandran, R., Wersinger, S.R., Soares-da-Silva, P., Liu, Z.F., Grinberg, A., Drago, J., Young, W.S., III, Westphal, H., Jose, P.A., and Sibley, D.R. (2002)
  • Mice Lacking D5 Dopamine Receptors Have Increased Sympathetic Tone and Are Hypertensive
  • The Journal of Neuroscience, 22, 10801-10810
  • 65) Kim, O.J., Ariano, M.A., Lazzarini, R.A., Levine, M.S., and Sibley, D.R (2002)
  • Neurofilament-M Interacts with the D1 Dopamine Receptor to Regulate Cell Surface Expression and Desensitization
  • Journal of Neuroscience, 22, 5920-5930
  • 66) Gardner, B. Liu, Z.F., Jiang, D., and Sibley, D.R. (2001)
  • The Role of Phosphorylation/Dephosphorylation in Agonist-Induced Desensitization of D1 Receptor Function: Evidence for a Novel Pathway for Receptor Dephosphorylation
  • Molecular Pharmacology, 59, 310-321
  • 67) Hunyady, B., Toth, Z., Palkovits, M., Mossik, G., Molnar, J., Feher, K., Zolyomi, A., Sibley, D.R. and Mezey, E. (2001)
  • Susceptibility of Dopamine D5 Receptor Targeted Mice to Cysteamine
  • Journal of Physiology (Paris), 95(1-6), 147-151
  • 68) Holmes, A., Hollon, T.R., Gleason, T.C., Liu, Z., Dreiling, J., Sibley, D.R., and Crawley, J.N., (2001)
  • Dopamine D5 Receptor Null Mutant Mice Show Attenuated Behavioral Responses to a Dopamine Agonist
  • Behavioral Neuroscience, 115, 1129-1144
  • 70) Schetz, J.A. and Sibley, D.R. (2000)
  • Tandem Sulfer-Containing Amino Acids are Epicritical Determinants of D2 Dopamine Receptor Pharmacology
  • European Journal of Pharmacology, 388, R5-R7
  • 71) Schetz, J.A., Benjamin, P.S., and Sibley, D.R. (2000)
  • Non-Conserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor are Molecular Determinants of D4-Selective Pharmacology
  • Molecular Pharmacology, 57, 144-152
  • 74) Jiang, D. and Sibley, D.R. (1999)
  • Agonist-induced Desensitization of D1 Dopamine Receptors with Mutations of Cyclic AMP-dependent Protein Kinase Phosphorylation Sites: Attenuation of the Rate of Agonist-induced Desensitization
  • Molecular Pharmacology, 56, 675-683
  • 76) Liu, L.-X., Burgess, L.H., Gonzalez, A.M., Sibley, D.R. and Chiodo, L.A. (1999)
  • D2S, D2L, D3 and D4 Dopamine Receptors Couple to a Voltage-Dependent Potassium Current in N18TG2 X Mesencephalon Hybrid Cells (MES-23.5) via Distinct G Proteins
  • Synapse, 31, 108-118
  • 77) Clifford, J.J., Tighe, O., Croke, D.T., Sibley, D.R., Drago, J., and Waddington, J.L. (1999)
  • Ethologically-based Topographical Evaluation of the Phenotype of Spontaneous Behaviour in Mice with Targeted Deletion of the D1A Dopamine Receptor: Paradoxical Elevation of Grooming Syntax
  • Neuroharmacology, 37, 1595-1602
  • 78) Cravchik, A., Sibley, D.R., and Gejman, P.V. (1999)
  • Differences in Neuroleptic Activity at the Human D2 Dopamine Receptor Missense Variants
  • Pharmacogenetics, 9, 17-23
  • 79) Lawler, C.P., Prioleau, C., Lewis, M.M., Mak, C., Jiang, D., Schetz, J.A., Gonzalez, A.M., Sibley, D.R. and Mailman, R.B. (1999)
  • The Molecular Pharmacology of the Novel Antipsychotic Aripiprazole (OPC-14597)
  • Neuropsychopharmacology, 20, 612-627
  • 80) Schetz, J.A. and Sibley, D.R. (1999)
  • Metal Cations as Atomic Scale Probes of G-Protein Coupled Receptor Structure and Function
  • Receptor Biochemistry and Methodology, 3, 121-140
  • 81) Cepeda, C., Li, Z., Cromwell, H.C., Altemus, K.L., Crawford, C.A., Nansen, E.A., Ariano, M.A., Sibley, D.R., Peacock, W.J., Mathern, G.G., and Levine, M.S. (1999)
  • Electrophysiological and Morphological Analyses of Cortical Neurons Obtained from Childen with Catastrophic Epilepsy: Dopamine Receptor Modulation of Glutaminergic Responses
  • Developmental Neuroscience, 21, 223-235
  • 82) Clifford, J.J., Tighe, O., Croke, D.T., Kinsella, A., Sibley, D.R., Drago, J. and Waddington, J.L. (1999)
  • Conservation of Behavioral Topography to Dopamine D1-like Receptor Agonists in Mutant Mice Lacking the D1A Receptor Implicates a D1-like Receptor not Coupled to Adenylyl Cyclase
  • Neuroscience, 93, 1483-1489
  • 83) El-Ghundi, M., Fletcher, P.J., Drago, J., Sibley, D.R., O'Dowd, B.F., and George, S.R. (1999)
  • Spatial Learning Deficit in Dopamine D1 Receptor Knockout Mice
  • , European Journal of Pharmacology, 383 , 95-106
  • 84) Rankin, M.L., and Sibley, D.R. (201)
  • Consitutive phosphorylation by protein kinase C regulates D1 dopamine receptor signaling
  • Journal of Neurochemistry, 115, 1655-1667
View Pubmed Publication
View/Hide All Publications